P/B
2,4
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
$17.7M
Market Cap • 9/15/2026
2008
(18 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
Switzerland
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,9
EPS
—
Market Cap
Market Cap
17,7M
EV
15,9M
EV/Revenue
0
EV/EBITDA
-6,3
EV/EBIT
-6,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-13,2%
Total Yield
-13,2%
Payout
0%
Retained Earnings
-84,9M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
14,5%
Capex/OCF
-0,3%
SBC/OCF
—
% PPE
0,8%
% Goodwill
15,1%
ROE
2225,2%
ROIC
—
Growth
CAGR Op. Income 5Y
2,2%
CAGR Net Income 5Y
23,7%
CAGR EPS 5Y
-57,9%
CAGR OCF 5Y
30,6%
Leverage
N.D./EBITDA
0,7
Debt/Equity
0%
Current Ratio
0,8
Quick Ratio
0,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!